Compare DETX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DETX | PASG |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 19.2M |
| IPO Year | N/A | 2020 |
| Metric | DETX | PASG |
|---|---|---|
| Price | $4.04 | $4.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 16.1K | ★ 93.7K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $3.29 |
| 52 Week High | $4.25 | $20.00 |
| Indicator | DETX | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 11.57 | 42.42 |
| Support Level | N/A | $3.94 |
| Resistance Level | $4.25 | $6.01 |
| Average True Range (ATR) | 0.21 | 0.52 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 24.45 | 45.18 |
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.